Brevan Howard Capital Management LP Protagonist Therapeutics, Inc Transaction History
Brevan Howard Capital Management LP
- $9.23 Billion
- Q1 2025
A detailed history of Brevan Howard Capital Management LP transactions in Protagonist Therapeutics, Inc stock. As of the latest transaction made, Brevan Howard Capital Management LP holds 16,114 shares of PTGX stock, worth $891,748. This represents 0.01% of its overall portfolio holdings.
Number of Shares
16,114Holding current value
$891,748% of portfolio
0.01%Shares
3 transactions
Others Institutions Holding PTGX
# of Institutions
298Shares Held
61.3MCall Options Held
1.01MPut Options Held
555K-
Farallon Capital Management LLC San Francisco, CA6.11MShares$338 Million1.7% of portfolio
-
Black Rock Inc. New York, NY5.76MShares$319 Million0.0% of portfolio
-
Rtw Investments, LP New York, NY5.72MShares$317 Million4.53% of portfolio
-
Vanguard Group Inc Valley Forge, PA4.28MShares$237 Million0.0% of portfolio
-
Deep Track Capital, LP Greenwich, CT3MShares$166 Million5.07% of portfolio
About Protagonist Therapeutics, Inc
- Ticker PTGX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 49,084,100
- Market Cap $2.72B
- Description
- Protagonist Therapeutics, Inc., a biopharmaceutical company, discovers and develops peptide-based therapeutic drugs to address hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing rusfertide (PTG-300), an injectable hepcidin mimetic that is in Phase II clinical trials for the treatment of patients with...